AMG National Trust Bank Boosts Stake in Abbott Laboratories $ABT

AMG National Trust Bank raised its stake in shares of Abbott Laboratories (NYSE:ABT) by 37.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 45,379 shares of the healthcare product maker’s stock after acquiring an additional 12,288 shares during the quarter. AMG National Trust Bank’s holdings in Abbott Laboratories were worth $4,659,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the stock. Brighton Jones LLC boosted its position in Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after purchasing an additional 4,755 shares in the last quarter. Sivia Capital Partners LLC lifted its position in shares of Abbott Laboratories by 3.5% during the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after buying an additional 162 shares during the last quarter. United Bank lifted its position in shares of Abbott Laboratories by 7.4% during the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after buying an additional 2,001 shares during the last quarter. Main Street Financial Solutions LLC boosted its holdings in shares of Abbott Laboratories by 13.6% in the 2nd quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock valued at $1,618,000 after buying an additional 1,428 shares in the last quarter. Finally, Canada Pension Plan Investment Board grew its position in shares of Abbott Laboratories by 25.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock worth $195,267,000 after buying an additional 292,547 shares during the last quarter. 75.18% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Leerink Partners decreased their target price on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a research report on Tuesday, April 21st. Robert W. Baird initiated coverage on Abbott Laboratories in a report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price objective for the company. Sanford C. Bernstein dropped their target price on Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. UBS Group reduced their target price on Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating on the stock in a research report on Monday, April 20th. Finally, Wells Fargo & Company lowered their price target on Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $117.61.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks bought 10,000 shares of Abbott Laboratories stock in a transaction that occurred on Monday, April 27th. The stock was purchased at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the acquisition, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Philip P. Boudreau bought 2,200 shares of the stock in a transaction dated Thursday, April 23rd. The stock was bought at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the purchase, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at approximately $201,300. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.46% of the stock is currently owned by corporate insiders.

Abbott Laboratories Trading Down 3.4%

NYSE ABT opened at $88.95 on Wednesday. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The company has a fifty day simple moving average of $89.27 and a two-hundred day simple moving average of $102.61. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The stock has a market cap of $154.94 billion, a P/E ratio of 24.92, a P/E/G ratio of 1.59 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. During the same period in the previous year, the company earned $1.09 earnings per share. The business’s quarterly revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, analysts forecast that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.8%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s payout ratio is presently 70.59%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.